DTP Communications

  • Resource for Providers

BC-CfE Resources for Providers (Poster)

  • Notification of Initiative Launch

Doxycycline for Bacterial STI Prevention

Click here to link to information about this initiative

  • Considerations for the Prescriber

Cabotegravir and Rilpivirine Extended-Release Injectable Suspensions (Cabenuva(R))

Cabotegravir and Rilpivirine Extended-Release Injectable Suspensions (Cabenuva(R))
Considerations for the Prescriber (June, 2023)
Considerations for the Client (May, 2023)
  • Formulary Addition

Doravirine (Pifeltro(R)) and Doravirine-lamivudine-tenofovir disoproxil fumarate (Delstrigo(R))

  • Notice to Prescribers

Updates to BC-CfE HIV Drug Treatment and Prevention Programs

  • Formulary Addition: Dolutegravir-lamivudine (Dovato®)
  • Resumption of routine HIV plasma viral load testing
  • Updates to BC-CfE Guidance Documents
  • Notice to Prescribers

Repeat Fill Authorization Permitted on BC-CfE Antiretroviral Prescriptions for the Treatment of HIV Infection

  • Guidance document

Guideline for Antiretroviral Therapy (ART) Regimens for Initial Therapy and for Switching ART in Virologically Stable Suppressed Adults

  • Notice

BC Ministry of Health Directive to Include Antiretrovirals on PharmaNet

  • Notice to Prescribers

BC-CfE AND COVID-19: HIV Treatment and Prevention Programs Update

  • BC-CfE Lab Notice to Prescribers

COVID-19 and how it will affect Precision Medicine testing

Scroll to Top

Start typing and press enter to search